Todd K. Rosengart

Add links
From Wikipedia, the free encyclopedia

Todd K. Rosengart (born January 24, 1960) is an American cardiothoracic surgeon, educator, and researcher, currently serving as the Chair of the Michael E. DeBakey Department of Surgery and Vice President for Hospital Operations and Quality Improvements at Baylor College of Medicine (BCM).[1][2] In addition, he serves as the DeBakey-Bard Chair and professor of heart and vascular disease at the Texas Heart Institute.[3] He has been a leading researcher in cardiac angiogenesis and regeneration and is known for performing the world's first viral-based gene cardiac transfer procedure.[4][5][6][7] and for his contributions to medical education and technology entrepreneurship.[8][9] Rosengart is recognized for his expertise in procedures such as bypass surgery, valve repair, minimally invasive surgery[10] and heart transplantation[11]

Early life and education[edit]

Born in Brooklyn, New York and brother to American lawyer, Mathew S. Rosengart.[12] He completed his M.D. with honors from Northwestern University in 1983 under the mentorship of Dr. Michael Lesch, known for co-discovering the Lesch-Nyhan syndrome.[13] After graduation, he completed an internship and residency in general surgery at New York University Medical Center in 1985, a research fellowship at the National Heart, Lung, and Blood Institute (NIH) in 1987, and a thoracic surgery residency at New York Hospital in 1991.[1] Furthering his training, Rosengart moved to London, UK, to become an honorary senior registrar at The Hospital for Sick Children. He completed his training at The Harley Street Clinic, working with Jaroslav Stark, a pioneer in the use of mathematics to study biological systems.[14]

Career[edit]

Prior to joining BCM, Rosengart held several significant positions at the State University of New York at Stony Brook (SUNY-Stony Brook), including professor and chair of the Department of Surgery and Chief of Cardiothoracic Surgery. He also served as the co-director of the Stony Brook Heart Center.[15]

In 2012, Rosengart joined Baylor College of Medicine, taking up multiple institutional roles, serving as the two-term chair of the BCM Faculty Group Practice Board of Governors and a member of the Baylor St. Luke's Medical Center Board of Directors.[2] Additionally, he served as the board chair of Affiliated Medical Services, a consortium of BCM and the University of Texas faculty staffing the Harris Health System.

Throughout his career, Rosengart has made substantial contributions to cardiothoracic surgery and heart and vascular disease education, noted for performing the world's first viral-based cardiac gene transfer procedure.[16] Rosengart has made progress in gene therapy to encourage the heart to grow new blood vessels, potentially offering a long-term cure for heart disease; already, over hundred patients have received the experimental therapy with encouraging results, with recent studies adding objective evidence of its effectiveness.[17] He is co-founder of Vitals.com, now one of the largest medical consumerism companies in the U.S. and XyloCor Therapeutics,[18][19] a gene therapy company. Moreover, he has secured approximately $20 million in research grants and holds thirteen U.S. patents.[16][20]

Research and publications[edit]

Rosengart is a respected researcher and NIH-funded scientist and has over 200 published papers credited to him, with more than 1,500 citations and an h-index of 61.[21][22] He served as the Editor-In-Chief of the Seminar in Thoracic and Cardiovascular Surgery from 2012 to 2020.[23]

Patents[edit]

Rosengart's research has generated 13 patents and applications, including:

  • Perfusion and occlusion device and method, (1999).[24]
  • Gene transfer therapy delivery device and method, (1998).[25]
  • Minimally invasive gene therapy delivery device, (1999).[26]
  • Method of expressing an exogenous nucleic acid, (2000).[27]
  • Method of inducing angiogenesis, (2001).[28]
  • Gene therapy platformed needle and method of administering a therapeutic solution to the heart, (2001).[29]
  • Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart, (2003).[30]
  • Multiple site delivery of adenoviral vector directly into muscle for the induction of angiogenesis, (2003).[31]
  • Method and apparatus for performing an anastomosis, (2006).[32]
  • Apparatus and method for cutting a heart valve, (2007).[33]
  • Method for determining the quality of a professional, (2014).[34]
  • Angiogenic conditioning to enhance cardiac cellular reprograming of fibroblasts of the infarcted myocardium, (2022).[35]

Memberships[edit]

He holds memberships in several professional societies, including the Leducq Foundation Scientific Advisory Committee, the American College of Cardiology, the American Association for Thoracic Surgery, the American College of Surgeons Academy of Master Surgeon Educations, and the American Surgical Association.[36] He served as president of the Society of Surgical Chairs (2019) and co-editor of the Seminars in Thoracic and Cardiovascular Surgery (2013-2016).[37][38] He is the current Society of Surgical Chair liaison member to the American College of Surgeons Surgical Research Committee and the American Association for Thoracic Surgery representative to the American College of Surgeons Board of Governors, for which he is vice chair of its Physician Competency and Health Workgroup.[39]

References[edit]

  1. ^ a b "trosenga". Baylor College of Medicine. Retrieved 2023-07-27.
  2. ^ a b "Baylor St. Luke's Medical Center Appoints Todd Rosengart, MD, to Hospital Board of Directors | St. Luke's Health | St. Luke's Health". stlukeshealth. Retrieved 2023-08-02.
  3. ^ "Todd Rosengart, MD". The Texas Heart Institute. Retrieved 2023-07-27.
  4. ^ Mathison, Megumi; Rosengart, Todd K. (2018-03-01). "Heart regeneration: The endothelial cell comes first". The Journal of Thoracic and Cardiovascular Surgery. 155 (3): 1128–1129. doi:10.1016/j.jtcvs.2017.09.106. ISSN 0022-5223. PMC 5819609. PMID 29452462.
  5. ^ Rosengart, T. K.; Lee, L. Y.; Patel, S. R.; Sanborn, T. A.; Parikh, M.; Bergman, G. W.; Hachamovitch, R.; Szulc, M.; Kligfield, P. D.; Okin, P. M.; Hahn, R. T.; Devereux, R. B.; Post, M. R.; Hackett, N. R.; Foster, T. (1999-08-03). "Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease". Circulation. 100 (5): 468–474. doi:10.1161/01.cir.100.5.468. ISSN 1524-4539. PMID 10430759. S2CID 5685867.
  6. ^ Rosengart, Todd K.; Lee, Leonard Y.; Patel, Shailen R.; Kligfield, Paul D.; Okin, Peter M.; Hackett, Neil R.; Isom, O. Wayne; Crystal, Ronald G. (October 1999). "Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA". Annals of Surgery. 230 (4): 466–70, discussion 470-2. doi:10.1097/00000658-199910000-00002. ISSN 0003-4932. PMC 1420895. PMID 10522716.
  7. ^ "Innovative approach brings cell-reprograming therapy for heart failure closer to reality". ScienceDaily. Retrieved 2023-08-02.
  8. ^ "Company". xylocor.com. Retrieved 2023-08-02.
  9. ^ AG, BIOCOM (2018-12-06). "XyloCor Therapeutics bags US$17m in Series A financing". european-biotechnology.com. Retrieved 2023-08-02.
  10. ^ "Minimally invasive procedure", Wikipedia, 2024-04-11, retrieved 2024-04-22
  11. ^ "Researchers explore novel strategy to improve the reprogramming efficiency of human fibroblasts". News-Medical.net. 2022-01-06. Retrieved 2023-08-02.
  12. ^ "The Man of Steel – Boston College Law School Magazine". Retrieved 2023-08-02.
  13. ^ Bell, Scott; Kolobova, Ilaria; Crapper, Liam; Ernst, Carl (2016-09-24). "Lesch-Nyhan Syndrome: Models, Theories, and Therapies". Molecular Syndromology. 7 (6): 302–311. doi:10.1159/000449296. ISSN 1661-8769. PMC 5131334. PMID 27920633.
  14. ^ "Jaroslav Stark". Imperial College London. Retrieved 2023-08-02.
  15. ^ "History of the Department | Renaissance School of Medicine at Stony Brook University". renaissance.stonybrookmedicine.edu. Retrieved 2023-08-02.
  16. ^ a b "Todd Rosengart, MD". The Texas Heart Institute. Retrieved 2023-08-02.
  17. ^ "TIME Magazine: How To Mend A Broken Heart --PAGE 1-- NOVEMBER 22, 1999". meiac.es. Retrieved 2023-08-02.
  18. ^ George, Cindy (2019-02-05). "Cardiothoracic surgeon Todd Rosengart, M.D., discusses his career as a medical problem-solver". TMC News. Retrieved 2023-08-02.
  19. ^ "Company". www.xylocor.com. Retrieved 2023-07-27.
  20. ^ "Google Patents". patents.google.com. Retrieved 2023-08-02.
  21. ^ "RePORT ⟩ RePORTER". reporter.nih.gov. Retrieved 2023-08-02.
  22. ^ "Rosengart T[author] - Search Results - PubMed". PubMed. Retrieved 2023-07-27.
  23. ^ "New Surgical Chairs Playbook Guides Current and Aspiring Surgical Leaders". ACS. Retrieved 2023-08-02.
  24. ^ US US5868764A, Rosengart, Todd K., "Perfusion and occlusion device and method", published 1999-02-09, assigned to Cornell Research Foundation Inc. 
  25. ^ US 5846225, Rosengart, Todd K.; Hartman, Raymond A. & Mack, III, Charles A., "Gene transfer therapy delivery device and method", published 1998-12-08, assigned to Cornell Research Foundation Inc. 
  26. ^ US 5997509, Rosengart, Todd K.; Crystal, Ronald G. & Hartman, Raymond A., "Minimally invasive gene therapy delivery device and method", published 1999-12-07, assigned to Cornell Research Foundation Inc. 
  27. ^ US 6165754, Crystal, Ronald G.; Zhou, Xiaohuai & Hackett, Neil R. et al., "Method of expressing an exogenous nucleic acid", published 2000-12-26, assigned to Cornell Research Foundation Inc. 
  28. ^ US 6329348, Crystal, Ronald G. & Rosengart, Todd K., "Method of inducing angiogenesis", published 2001-12-11, assigned to Cornell Research Foundation Inc. 
  29. ^ WO application 2001010315, Rosengart, Todd K. & Crystal, Ronald G., "Gene therapy platformed needle and method of administering a therapeutic solution to a heart", published 2001-02-15, assigned to Cornell Research Foundation Inc. , application discontinued.
  30. ^ US 6508802, Rosengart, Todd K. & Crystal, Ronald G., "Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart", published 2003-01-21, assigned to Cornell Research Foundation Inc. 
  31. ^ US 6518255, Rosengart, Todd K. & Crystal, Ronald G., "Multiple site delivery of adenoviral vector directly into muscle for the induction of angiogenesis", published 2003-02-11, assigned to Cornell Research Foundation Inc. 
  32. ^ US 7066953, Rosengart, Todd K., "Method and apparatus for performing an anastamosis", published 2006-06-27 
  33. ^ US 7255706, Rosengart, Todd K., "Apparatus and method for cutting a heart valve", published 2007-08-14 
  34. ^ US 8694441, Rothschild, Mitchel; Parlamis, Christine & Rosengart, Todd, "Method for determining the quality of a professional", published 2014-04-08, assigned to MDX Medical Inc. 
  35. ^ US application 2022088143, Crystal, Ronald G.; Rosengart, Todd K. & Gersch, Robert et al., "Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium", published 2022-03-24, assigned to Cornell University and The Research Foundation of State University of New York 
  36. ^ "Leadership |". Retrieved 2023-08-02.
  37. ^ "Membership Directory - Society of Surgical Chairs". web4.facs.org. Retrieved 2023-08-02.
  38. ^ "Dr. Todd K. Rosengart Appointed Co-Editor of Seminars in Thoracic and Cardiovascular Surgery | Renaissance School of Medicine at Stony Brook University". renaissance.stonybrookmedicine.edu. Retrieved 2023-08-02.
  39. ^ "ACS Surgical Research Committee and the American Association for Thoracic Surgery representative to the American College of Surgeons Board of Governors, for which he is vice chair of its Physician Competency and Health Workgroup". ACS. Retrieved 2023-08-02.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Todd_K._Rosengart&oldid=1220208136"